AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, FY2021
-0.6%
Period ended Dec 31, 2021
Change on a year earlier
+1.3 pts
-1.9% in FY2020
History
2 years
Since FY2020
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | -0.6% | +1.3 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | -1.9% | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Cite this data
StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] — Worldwide reported growth YoY (%) (%), annual FY2020–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid_ww_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.